Dr Reddys Laboratories Limited's Board of Directors has declared and approved a final dividend of ₹8 per equity share of ₹1 each for the financial year ending March 31, 2025.
The company's Board of Directors has recommended a final dividend of ₹8 per equity share of ₹1 each for the financial year 2024–25. The 41st Annual General Meeting (AGM) of the company’s members is scheduled to be held on Thursday, July 24, 2025.
The company has fixed July 10, 2025, as the record date to determine the members eligible to receive the final dividend for the financial year ended March 31, 2025.
For the financial year 2025, the company reported a revenue of ₹325,535 million, reflecting a rise from ₹279,164 million in FY2024. Gross profit also saw notable growth, reaching ₹190,428 million in FY2025 compared to ₹163,607 million in the previous year. Additionally, EBITDA stood at ₹92,133 million in FY2025, up from ₹83,013 million in FY2024, indicating improved operational efficiency and profitability.
On July 8, 2025, Dr Reddys Laboratories share price (NSE: DRREDDY) opened at ₹1,310.30 and closed at ₹1,284.00, down by 2.02%. The stock price touched its day’s low at ₹1,273.60.
Also Read: Best Pharma Stocks in July 2025!
Dr. Reddy's Laboratories Ltd is a prominent pharmaceutical company based in India, offering a diverse range of products and services such as Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations.
The company's last dividend declaration was a final dividend of ₹40 per share, with a record date of July 16, 2024. With the newly approved dividend, shareholders can anticipate continued returns.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 9, 2025, 8:00 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
